BioCentury
ARTICLE | Company News

Furen gets rights to AZD0364 from AstraZeneca

December 21, 2018 7:30 PM UTC

Shanghai Furen Medicine R&D Co. Ltd. (Shanghai, China) gained Chinese rights to cancer candidate AZD0364 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Shanghai Furen is a subsidiary of Furen Medicines Group Co. Ltd. (Zhengzhou, China).

AZD0364 is a dual inhibitor of MAP kinase 1 (MAPK1; ERK-2) and MAPK3 (ERK-1). AstraZeneca has submitted an IND for the compound to treat non-small cell lung cancer (NSCLC) and solid tumors...